Gwenaëlle Garin

Safety and Efficacy of the mTOR Inhibitor, Vistusertib, Combined With Anastrozole in Patients With Hormone Receptor−Positive Recurrent or Metastatic Endometrial Cancer

Pierre‐Etienne Heudel, Jean‐Sébastien Frenel, Cécile Dalban et al. · JAMA Oncology · 2022 · 79 citations · Full text

Medicine, Oncology, Pharmacology +16

A first-in-human study investigating biodistribution, safety and recommended dose of a new radiolabeled MAb targeting FZD10 in metastatic synovial sarcoma patients

Anne‐Laure Giraudet, Philippe A. Cassier, Chicaco Iwao-Fukukawa et al. · BMC Cancer · 2018 · 65 citations · Full text

Medicine, Nuclear Medicine, Oncology +17

The CSF-1R inhibitor pexidartinib affects FLT3-dependent DC differentiation and may antagonize durvalumab effect in patients with advanced cancers

Aurélien Voissière, Carlos Gomez‐Roca, Sylvie Chabaud et al. · Science Translational Medicine · 2024 · 54 citations

Medicine, Oncology, Pharmacology +17

MEDIPLEX: A phase 1 study of durvalumab (D) combined with pexidartinib (P) in patients (pts) with advanced pancreatic ductal adenocarcinoma (PDAC) and colorectal cancer (CRC).

Philippe A. Cassier, Gwenaëlle Garin, Lauriane Eberst et al. · Journal of Clinical Oncology · 2019 · 48 citations

Medicine, Oncology, Pharmacology +17

3D absorbed dose distribution estimated by Monte Carlo simulation in radionuclide therapy with a monoclonal antibody targeting synovial sarcoma

David Sarrut, Jean‐Noël Badel, Adrien Halty et al. · EJNMMI Physics · 2017 · 18 citations · Full text

Medicine, Nuclear Medicine, Radiology +17